Noble Life Sciences Acquires Spring Valley Laboratories
News Dec 04, 2014
Noble Life Sciences has announced the acquisition of Spring Valley Laboratories (Sykesville, MD), a full service, GLP (Good Laboratory Practice)-compliant, preclinical contract research organization (CRO) for the development of drugs, vaccines, and medical devices.
The acquisition greatly expands Noble’s services to include GLP regulatory standards, studies in small and large animals, and testing capabilities for vaccines and medical devices.
Combined with Noble’s recognized strength conducting studies directed at early-stage products, the acquisition of Spring Valley Laboratories extends the Company’s suite of offerings across the full continuum of preclinical studies from initial product discovery through regulation-compliant studies for submission to FDA and other similar agencies.
Founded in 1980, Spring Valley Laboratories has extensive experience in vaccine and drug toxicity, medical devices, GLP in vivo product release tests, derivation and maintenance of animal breeding colonies, production of custom antibodies, and development of animal models. The company provides all aspects of the process from design to regulatory support of IND, IDE, or PMA submissions.
Alain Cappeluti, President of Noble Life Sciences, said, “Spring Valley Laboratories’ GLP and large animal testing capabilities will be an excellent fit with our small animal testing capabilities and in vitro drug discovery expertise. This will enable us to engage with our clients throughout the preclinical development process."
Spring Valley Laboratories’ facilities consist of 24,000 square feet of animal housing, support, and laboratory space securely situated on a twenty-five acre campus including 8,000 sq. ft. of conventional and 14,000 sq. ft. of specific pathogen free (SPF) housing and support space for both small and large animals. Support spaces include two surgical suites with recovery room, intensive care area, and preparation area as well as laboratories for clinical pathology, designated test article storage and preparation, specimen analysis, necropsy and secure access-controlled archives.
Amy Dyke, President and CEO of Spring Valley Laboratories, commented, "I'm thrilled with the acquisition by Noble Life Sciences. Our GLP-compliant safety and efficacy testing services will expand Noble’s early stage research services. This definitely enhances our combined offerings for clients developing drugs, vaccines, and medical devices.”
Spring Valley Laboratories will become a division of Noble Life Sciences; Mr. Cappeluti will serve as President of the division. No staff changes at Spring Valley Laboratories are currently contemplated; Ms. Dyke and Robyn Shaw, the previous owners, will continue to provide their operational expertise.
You Are What Your Mother EatsNews
While many factors, such as the age of the mother, overall health and genetics ultimately play a role, the correlation between a mother’s nutrition habits and metabolism has been proved to directly impact the growth of her child. And researchers believe they may be one step closer to knowing why.READ MORE
Pigs as Models for Zika Virus ResearchNews
Zika virus is pathogenic to humans and nonhuman primates but does not naturally affect other species, complicating studies on pathogenesis and the evaluation of vaccines and antiviral therapies. Due to the similarities in physiology, anatomy and the immune system between pigs and humans it was evaluated if pigs can be used as human surrogates in Zika virus research.READ MORE
Immune Cells Form Clots in Tumors Aiding Lung Cancer's SpreadNews
Researchers have found that by helping to form clots within tumors, immune cells that flock to a particular type of lung cancer are actually building a foundation for the tumor to spread within the body.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018